High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years

Cancer

Volumn 118, Issue 2, 2012, Pages 428-433

  Arellano, Martha ^a   Winton, Elliott ^a   Pan, Lin ^b   Lima, Lisa ^a   Tighiouart, Mourad ^b   Bhalla, Kapil ^c   Heffner, Leonard T ^a   Neely, Jessica ^a   Hutcherson, Donald ^a   McLemore, Morgan ^a   Langston, Amelia ^a   Khoury, H Jean ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; Elderly; High dose cytarabine; Outcomes

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; AGING; ARTICLE; BRAIN HEMORRHAGE; BRAIN TOXICITY; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLAR ATAXIA; CONGESTIVE HEART FAILURE; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA REMISSION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEPSIS; STROKE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; COMORBIDITY; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84855478375     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26290     Document Type: Article

References (28)

1. Altekruse SF, Kosary CL, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2007 [based on November 2009 SEER data submission, posted to the SEER web site 2010]. Bethesda, MD: National Cancer Institute; 2010.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
3. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-1603. (Pubitemid 34773427)
4. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without alltrans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124. (Pubitemid 46435390)
5. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136:624-627. (Pubitemid 46148199)
6. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
7. Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806-1813.
8. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials. Cancer. 2006;107:116-124. (Pubitemid 43939038)
9. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331:896-903. (Pubitemid 24299870)
10. Lazarus HM, Vogler WR, Burns CP, Winton EF. Highdose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group. Cancer. 1989;63:1055-1059. (Pubitemid 19074730)
11. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116: 4422-4429.
12. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851. (Pubitemid 26357364)
13. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediatedose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993;10(suppl):115-121. (Pubitemid 23120976)
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
15. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432. (Pubitemid 30017051)
16. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083.
17. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
18. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246-4254. (Pubitemid 47554249)
19. Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev. 2009;35:97-120.
20. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40 101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007;25:25-31. (Pubitemid 350003047)
21. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116:3622-3626.
22. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:596-604.
23. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): 2 multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985;3:1583-1589. (Pubitemid 16199209)
24. Rees JK, Gray RG, Swirsky D, Hayhoe FG. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet. 1986;2:1236-1241. (Pubitemid 17182837)
25. Preisler H, Davis RB, Kirshner J, et al. Comparison of 3 remission induction regimens and 2 postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood. 1987;69:1441-1449. (Pubitemid 17085306)
26. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103-1111.
27. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872-881. (Pubitemid 28115455)
28. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28:549-555.